News

Fact checked by Nick Blackmer I was first told that I was at higher risk for fatty liver disease in 2005. I had never heard ...
Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...
Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...
A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.
The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...
A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...
The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...
AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...
A latest study has shown promising results in people suffering from metabolic dysfunction-associated steatohepatitis (MASH), ...
The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.
A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...